Palleon Pharmaceuticals to Present Preclinical Data on EAGLE-Her2 and Anti-Siglec-9 Antibody Programs at the 11th Annual Protein & Antibody Engineering Summit

WALTHAM, Mass., November 19, 2019 – Palleon Pharmaceuticals, a leading biotech company developing drugs that target the Siglec-Sialoglycan axis to treat cancer, will present preclinical data from two of its development programs today at the 11th Annual Protein & Antibody Engineering Summit (PEGS Europe) in Lisbon, Portugal.

The Siglec-Sialoglycan axis, a previously underappreciated mechanism of immunosuppression in cancer, has recently emerged as a major tumor immune escape pathway. Palleon has leveraged its proprietary EAGLE and CONVERGENCE platforms to develop a suite of technologies that target both Siglec receptors and their sialoglycan ligands.

Li Peng, Ph.D., Senior Vice President of Research and Early Product Development at Palleon, will present preclinical data on the company’s lead candidate EAGLE-Her2, showing that selectively removing the terminal sialic acids of sialoglycans within the tumor microenvironment effectively inhibits the Siglec-Sialoglycan immune checkpoint and reinvigorates both the innate and adaptive responses to cancer. In addition, Dr. Peng will present Palleon’s anti-Siglec-9 monoclonal antibody program, including preclinical studies that detail the development of antagonistic anti-Siglec antibodies that block the Siglec-Sialoglycan axis.

Palleon Scientific Advisor, Joy Burchell, Ph.D. and Professor of Glyco-Oncology at Kings College London will also present at PEGS Europe. Dr. Burchell will discuss the role of a glycosylated form of tumor-associated mucin MUC1, which engages with Siglec-9 on monocytes and macrophages to create an immunosuppressive tumor microenvironment.

“Targeting the Siglec-Sialoglycan axis of immunosuppression is a truly novel approach to treating cancer that could potentially benefit patients who are resistant to first-generation immuno-oncology therapies,” said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. “Our preclinical data demonstrates striking single agent efficacy across a range of animal models and human in vitro systems.”

About Palleon Pharmaceuticals

Palleon Pharmaceuticals is the leading biotechnology company developing drugs that target the Siglec-Sialoglycan axis to treat cancer. The company’s proprietary EAGLE, CONVERGENCE and HYDRA platforms integrate technologies and insights from world-renowned scientific leaders in the glyco-immunology field to create a novel approach to treating cancer. By enabling an anti-cancer response from multiple immune cell types, inhibiting glyco-immune checkpoints will tackle resistance to existing immuno-oncology agents and make possible a wider range of rational combination therapies to treat cancer. Palleon has several cancer drug discovery programs underway. Beyond oncology, other important areas where glyco-immune checkpoints may play a role include inflammatory and fibrotic diseases, neurodegenerative disease and chronic viral infections. The company is advancing its pipeline and development programs with a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures and AbbVie Ventures. Learn more at

Palleon Media Contact
Krystle Gibbs
Ten Bridge Communications
(508) 479-6358